ASSOCIATION OF THYROID DYSFUNCTION WITH DEVELOPMENT OF POLYCYSTIC OVARIAN SYNDROME AMONG REPRODUCTIVE AGE WOMEN OF SIALKOT, PAKISTAN
DOI:
https://doi.org/10.54112/bcsrj.v2024i1.1038Keywords:
Acanthosis Nigricans, Hirsutism, Polycystic Ovary Syndrome, Thyroid Diseases, Thyroxine, TriiodothyronineAbstract
Polycystic Ovary Syndrome (PCOS) is a prevalent hormonal disorder among women of reproductive age, often co-occurring with metabolic syndromes such as thyroid dysfunction. Understanding this association is crucial for addressing the broader reproductive and general health implications. Objective: This study aims to investigate the association between thyroid dysfunction and the development of PCOS in women of reproductive age in Sialkot, Pakistan. Methods: This prospective study was conducted from May 2023 to May 2024 at Civil Hospital, Sardar Begum Hospital, Cheema Family Hospital, and Waleed Hospital. A total of 100 females were included, divided into two groups: 50 in the control group (no disease) and 50 in the treatment group with both thyroid dysfunction and PCOS. Participants aged 23 to 45 were selected from medicine and gynecology wards. Blood samples were analyzed for thyroid function, and a comprehensive questionnaire was administered to assess the prevalence and characteristics of symptoms related to PCOS and thyroid dysfunction. Statistical analysis was performed using T-tests to compare mean values of Triiodothyronine (T3) and Thyroxine (T4) between groups. Results: The treatment group exhibited a significant prevalence of symptoms: 80% reported hirsutism, 92% had irregular menstrual cycles, 72% experienced weight gain, 60% suffered from hair loss, 76% had acne and high blood pressure, and 64% showed signs of Acanthosis nigricans. Significant differences in thyroid hormone levels were observed, with mean T3 levels at 9.4718 (SE = 1.7373, 95% CI [5.9783, 12.9653], T = 5.4525, p < 0.05) and mean T4 levels at 51.172 (SE = 6.7027, 95% CI [37.6952, 64.6508], T = 7.6333, p < 0.05) as compared to control group. Conclusion: The findings highlight a significant association between thyroid dysfunction and PCOS, with thyroid dysfunction impacting T3 and T4 levels in patients with PCOS. This underscores the need for targeted thyroid screening in PCOS patients to manage and mitigate the broader health implications effectively.
Downloads
References
Adebisi OD, Denwigwe-aggrey BC, Tairu AB, Ozoemena N, David JF, Monday EO. The effect of polycystic ovarian syndrome on the mental health of women of reproductive age. International Journal of Research in Medical Sciences. 2021;9(6):1741.
Zeng X, Xie Y-j, Liu Y-t, Long S-l, Mo Z-c. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clinica chimica acta. 2020;502:214-21.
Jeanes YM, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutrition research reviews. 2017;30(1):97-105.
Muñoz Yáñez C, García Vargas G, Pérez-Morales R. Monogenic, polygenic and multifactorial obesity in children: Genetic and environmental factors. Austin J Nutr Metab. 2017;4(3):1052.
Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine reviews. 2016;37(5):467-520.
Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nature reviews Disease primers. 2016;2(1):1-18.
Mobeen H, Afzal N, Kashif M. Polycystic ovary syndrome may be an autoimmune disorder. Scientifica. 2016;2016(1):4071735.
Batóg G, Dołoto A, Bąk E, Piątkowska-Chmiel I, Krawiec P, Pac-Kożuchowska E, et al. The interplay of oxidative stress and immune dysfunction in Hashimoto’s thyroiditis and polycystic ovary syndrome: a comprehensive review. Frontiers in Immunology. 2023;14:1211231.
Brown ED, Obeng-Gyasi B, Hall JE, Shekhar S. The thyroid hormone axis and female reproduction. International Journal of Molecular Sciences. 2023;24(12):9815.
Palomba S, Colombo C, Busnelli A, Caserta D, Vitale G. Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature. Frontiers in Endocrinology. 2023;14:1251866.
Li Y, Chen C, Ma Y, Xiao J, Luo G, Li Y, et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life sciences. 2019;228:167-75.
Zhu T, Goodarzi MO. Causes and consequences of polycystic ovary syndrome: insights from Mendelian randomization. The Journal of Clinical Endocrinology & Metabolism. 2022;107(3):e899-e911.
Zwain ZM, Aziz MK. Polycystic ovarian syndrome and thyroid disorders. International Journal of Technology and Research. 2016;4:73-7.
Pervin HH, Kazal RK, Rahman AS, Pervin T, Fatema K, Chowdhury SA, et al. Thyroid disorders in women with polycystic ovary syndrome. Journal of Biosciences and Medicines. 2020;8(04):128.
van der Ham K, Stekelenburg KJ, Louwers YV, van Dorp W, Schreurs MW, van der Wal R, et al. The prevalence of thyroid dysfunction and hyperprolactinemia in women with PCOS. Frontiers in Endocrinology. 2023;14:1245106.
Cai J, Zhang Y, Wang Y, Li S, Wang L, Zheng J, et al. High thyroid stimulating hormone level is associated with hyperandrogenism in euthyroid polycystic ovary syndrome (PCOS) women, independent of age, BMI, and thyroid autoimmunity: a cross-sectional analysis. Frontiers in Endocrinology. 2019;10:222.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 I RASHEED , S ASHRAF , Q SHAKEEL , LN BUTT , D SHAHWAR , MA MURAD , HA ISHAQ
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.